The gut microbial metabolite formate exacerbates colorectal cancer progression

The gut microbiome is a key player in the immunomodulatory and protumorigenic microenvironment during colorectal cancer (CRC), as different gut-derived bacteria can induce tumour growth. However, the crosstalk between the gut microbiome and the host in relation to tumour cell metabolism remains largely unexplored. Here we show that formate, a metabolite produced by the CRC-associated bacterium Fusobacterium nucleatum, promotes CRC development. We describe molecular signatures linking CRC phenotypes with Fusobacterium abundance. Cocultures of F. nucleatum with patient-derived CRC cells display protumorigenic effects, along with a metabolic shift towards increased formate secretion and cancer glutamine metabolism. We further show that microbiome-derived formate drives CRC tumour invasion by triggering AhR signalling, while increasing cancer stemness. Finally, F. nucleatum or formate treatment in mice leads to increased tumour incidence or size, and Th17 cell expansion, which can favour proinflammatory profiles. Moving beyond observational studies, we identify formate as a gut-derived oncometabolite that is relevant for CRC progression

Microbiome in Colorectal Cancer: How to Getfrom Meta-omics to Mechanism?

Mounting evidence from metagenomic analyses suggests that a state of pathological microbial imbalance or dysbiosis is prevalent in the gut of patients with colorectal cancer. Several bacterial taxa have been identified of which representative isolate cultures interact with human cancer cells in vitro and trigger disease path-ways in animal models. However, how the complex interrelationships in dysbiotic communities may be involved in cancer pathogenesis remains a crucial question.Here, we provide a survey of current knowledge of the gut microbiome in colorectal cancer. Moving beyond observational studies, we outline new experimental approaches for gaining ecosystem-level mechanistic understanding of the gut microbiome’s role in cancer pathogenesi

Evolution of the murine gut resistome following broad-spectrum antibiotic treatment.

The emergence and spread of antimicrobial resistance (AMR) represent an ever-growing healthcare challenge worldwide. Nevertheless, the mechanisms and timescales shaping this resistome remain elusive. Using an antibiotic cocktail administered to a murine model along with a longitudinal sampling strategy, we identify the mechanisms by which gut commensals acquire antimicrobial resistance genes (ARGs) after a single antibiotic course. While most of the resident bacterial populations are depleted due to the treatment, Akkermansia muciniphila and members of the Enterobacteriaceae, Enterococcaceae, and Lactobacillaceae families acquire resistance and remain recalcitrant. We identify specific genes conferring resistance against the antibiotics in the corresponding metagenome-assembled genomes (MAGs) and trace their origins within each genome. Here we show that, while mobile genetic elements (MGEs), including bacteriophages and plasmids, contribute to the spread of ARGs, integrons represent key factors mediating AMR in the antibiotic-treated mice. Our findings suggest that a single course of antibiotics alone may act as the selective sweep driving ARG acquisition and incidence in gut commensals over a single mammalian lifespan

Understanding the role of Fusobacterium nucleatum metabolism in colon cancer initiation and progression

Accumulating evidence suggests that dysbiosis, a state of pathological imbalance in the human gut microbiome, is present in patients suffering from colorectal cancer (CRC). 16S rRNA gene sequencing, as well as metagenomic and metatranscriptomic analyses, identified specific bacteria being associated with CRC. Among others, Fusobacterium ssp. have been found to directly interact with cancer or immune cells of their host. However, only a limited number of CRC-associated microbes have been examined for host-microbial interactions and, as such, the role of bacteria in the etiology of the disease remains largely elusive. Our aim is the development of predictive and experimental models that allow to not only study the host-microbiota interactions but are also amenable to high-throughput experimentation and large-scale omics-data integration. Ultimately, such models should help to get from meta-omics to cellular mechanism and, moreover, serve as tools for reproducible analyses of host-microbial interaction mechanisms of on a transcriptomic, proteomic, and metabolomic level. Our research proposes an integrative study approach allowing us to bridge meta-omics with functional mechanisms by focusing on the interaction taking place between F. nucleatum and patient-derived CRC cells